ADC Therapeutics (ADCT) CMO has 41,068 shares withheld for RSU taxes

Rhea-AI Filing Summary

ADC Therapeutics SA reported an insider equity transaction involving its Chief Medical Officer, Mohamed Zaki. On 12/06/2025, the company withheld 41,068 common shares at a price of $3.29 per share to cover his tax withholding obligations tied to previously granted restricted share units that vested. After this automatic withholding, Zaki beneficially owns 421,820 common shares, held directly. This type of transaction reflects routine share withholding for taxes rather than an open-market sale.

Insider Trade Summary

Net Seller: 41,068 shares

Net Sell 1 txn

Insider Zaki Mohamed

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	41,068	$3.29	$135K

Holdings After Transaction: Common Shares — 421,820 shares (Direct)

Footnotes (1)

1. F1. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/09/2025 - 05:09 PM Learn about SEC filing dates

FAQ

What insider transaction did ADC Therapeutics (ADCT) report for Mohamed Zaki?

ADC Therapeutics reported that Chief Medical Officer Mohamed Zaki had 41,068 common shares withheld on 12/06/2025 to satisfy tax obligations from vested restricted share units.

Did Mohamed Zaki sell ADC Therapeutics (ADCT) shares on the open market?

No. The filing states that the 41,068 common shares represent shares withheld by the issuer to satisfy tax withholding obligations upon vesting of restricted share units, not an open-market sale.

How many ADC Therapeutics (ADCT) shares does Mohamed Zaki own after this transaction?

Following the reported transaction, Mohamed Zaki beneficially owns 421,820 common shares of ADC Therapeutics, held directly.

What was the price used for the ADC Therapeutics (ADCT) tax withholding shares?

The 41,068 ADC Therapeutics common shares withheld for taxes were valued at a price of $3.29 per share in the transaction record.

What is the role of the reporting person in ADC Therapeutics (ADCT)?

The reporting person, Mohamed Zaki, is identified as an officer of ADC Therapeutics with the title Chief Medical Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaki Mohamed

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/06/2025		F(1)		41,068	D(1)	$3.29	421,820	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, Attorney-in-Fact for Mohamed Zaki	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.